Clinical TrialJun 1, 2026, 09:13 AM
Oncolytics Biotech Announces Positive Preclinical Data for Pelareorep
AI Summary
Oncolytics Biotech Inc. announced positive initial preclinical data for pelareorep in combination with RAS inhibitor modalities, demonstrating greater anti-tumor activity than individual approaches. Based on these findings, the company plans additional studies in pancreatic and colorectal cancer models to further evaluate immune activation, tumor response durability, and time-to-resistance. These results support pelareorep's potential as an immune-priming backbone for next-generation targeted therapies, particularly for difficult-to-treat RAS-mutated tumors.
Key Highlights
- Initial preclinical data for pelareorep with RAS inhibitor modalities showed greater anti-tumor activity.
- Oncolytics Biotech plans additional studies in pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) models.
- Studies will evaluate pelareorep with KRAS G12C inhibitors, pan-RAS inhibitors, and next-generation RAS pathway agents.
- Full results from the initial preclinical studies are expected to be presented in fall or winter of 2026.
- Pelareorep is an investigational immunotherapy promoting immune responses and tumor-infiltrating lymphocytes.
Price Impact
More from ONCY